A citation-based method for searching scientific literature

Glen J Titmarsh, Andrew S Duncombe, Mary Frances McMullin, Michael O'Rorke, Ruben Mesa, Frank De Vocht, Sarah Horan, Lin Fritschi, Mike Clarke, Lesley A Anderson. Am J Hematol 2014
Times Cited: 106







List of co-cited articles
716 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Daniel A Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, Michelle M Le Beau, Clara D Bloomfield, Mario Cazzola, James W Vardiman. Blood 2016
54

Somatic mutations of calreticulin in myeloproliferative neoplasms.
Thorsten Klampfl, Heinz Gisslinger, Ashot S Harutyunyan, Harini Nivarthi, Elisa Rumi, Jelena D Milosevic, Nicole C C Them, Tiina Berg, Bettina Gisslinger, Daniela Pietra,[...]. N Engl J Med 2013
35

Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Odile Moulard, Jyotsna Mehta, Jon Fryzek, Robert Olivares, Usman Iqbal, Ruben A Mesa. Eur J Haematol 2014
122
32

A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Robert Kralovics, Francesco Passamonti, Andreas S Buser, Soon-Siong Teo, Ralph Tiedt, Jakob R Passweg, Andre Tichelli, Mario Cazzola, Radek C Skoda. N Engl J Med 2005
30

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
J Nangalia, C E Massie, E J Baxter, F L Nice, G Gundem, D C Wedge, E Avezov, J Li, K Kollmann, D G Kent,[...]. N Engl J Med 2013
29

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
E Joanna Baxter, Linda M Scott, Peter J Campbell, Clare East, Nasios Fourouclas, Soheila Swanton, George S Vassiliou, Anthony J Bench, Elaine M Boyd, Natasha Curtin,[...]. Lancet 2005
27

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L Levine, Martha Wadleigh, Jan Cools, Benjamin L Ebert, Gerlinde Wernig, Brian J P Huntly, Titus J Boggon, Iwona Wlodarska, Jennifer J Clark, Sandra Moore,[...]. Cancer Cell 2005
24

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Ayalew Tefferi, Paola Guglielmelli, Dirk R Larson, Christy Finke, Emnet A Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A Belachew, Terra L Lasho,[...]. Blood 2014
419
24

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Yana Pikman, Benjamin H Lee, Thomas Mercher, Elizabeth McDowell, Benjamin L Ebert, Maricel Gozo, Adam Cuker, Gerlinde Wernig, Sandra Moore, Ilene Galinsky,[...]. PLoS Med 2006
22

Epidemiology of myeloproliferative neoplasms in the United States.
Jyotsna Mehta, Hongwei Wang, Sheikh Usman Iqbal, Ruben Mesa. Leuk Lymphoma 2014
142
21

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
James W Vardiman, Jüergen Thiele, Daniel A Arber, Richard D Brunning, Michael J Borowitz, Anna Porwit, Nancy Lee Harris, Michelle M Le Beau, Eva Hellström-Lindberg, Ayalew Tefferi,[...]. Blood 2009
19

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
Chloé James, Valérie Ugo, Jean-Pierre Le Couédic, Judith Staerk, François Delhommeau, Catherine Lacout, Loïc Garçon, Hana Raslova, Roland Berger, Annelise Bennaceur-Griscelli,[...]. Nature 2005
19

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Tiziano Barbui, Giovanni Barosi, Gunnar Birgegard, Francisco Cervantes, Guido Finazzi, Martin Griesshammer, Claire Harrison, Hans Carl Hasselbalch, Rudiger Hehlmann, Ronald Hoffman,[...]. J Clin Oncol 2011
543
17

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Linda M Scott, Wei Tong, Ross L Levine, Mike A Scott, Philip A Beer, Michael R Stratton, P Andrew Futreal, Wendy N Erber, Mary Frances McMullin, Claire N Harrison,[...]. N Engl J Med 2007
899
17

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Tiziano Barbui, Juergen Thiele, Francesco Passamonti, Elisa Rumi, Emanuela Boveri, Marco Ruggeri, Francesco Rodeghiero, Emanuele S G d'Amore, Maria Luigia Randi, Irene Bertozzi,[...]. J Clin Oncol 2011
317
16

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V Catalano, Michael Deininger, Carole Miller, Richard T Silver,[...]. N Engl J Med 2012
16

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
Francesco Passamonti, Elisa Rumi, Ester Pungolino, Lucia Malabarba, Paola Bertazzoni, Marina Valentini, Ester Orlandi, Luca Arcaini, Ercole Brusamolino, Cristiana Pascutto,[...]. Am J Med 2004
310
15

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes, Brigitte Dupriez, Arturo Pereira, Francesco Passamonti, John T Reilly, Enrica Morra, Alessandro M Vannucchi, Ruben A Mesa, Jean-Loup Demory, Giovanni Barosi,[...]. Blood 2009
842
15

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
Roberto Marchioli, Guido Finazzi, Raffaele Landolfi, Jack Kutti, Heinz Gisslinger, Carlo Patrono, Raphael Marilus, Ana Villegas, Gianni Tognoni, Tiziano Barbui. J Clin Oncol 2005
474
15

Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Samer A Srour, Susan S Devesa, Lindsay M Morton, David P Check, Rochelle E Curtis, Martha S Linet, Graça M Dores. Br J Haematol 2016
102
15

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
A Tefferi, E Rumi, G Finazzi, H Gisslinger, A M Vannucchi, F Rodeghiero, M L Randi, R Vaidya, M Cazzola, A Rambaldi,[...]. Leukemia 2013
397
15

Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
Christina Roaldsnes, René Holst, Henrik Frederiksen, Waleed Ghanima. Eur J Haematol 2017
26
57

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger, Hans Michael Kvasnicka, Alessandro M Vannucchi, Paola Guglielmelli, Attilio Orazi, Ayalew Tefferi. Blood Cancer J 2018
250
15

Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.
Malin Hultcrantz, Sigurdur Yngvi Kristinsson, Therese M-L Andersson, Ola Landgren, Sandra Eloranta, Asa Rangert Derolf, Paul W Dickman, Magnus Björkholm. J Clin Oncol 2012
146
14

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S Hunter, Richard Levy, Laurent Knoops,[...]. N Engl J Med 2012
14

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).
Tiziano Barbui, Guido Finazzi, Alessandra Carobbio, Juergen Thiele, Francesco Passamonti, Elisa Rumi, Marco Ruggeri, Francesco Rodeghiero, Maria Luigia Randi, Irene Bertozzi,[...]. Blood 2012
336
13

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
Francesco Passamonti, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Elisa Rumi, Arturo Pereira, Paola Guglielmelli, Ester Pungolino, Marianna Caramella, Margherita Maffioli,[...]. Blood 2010
613
13

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Elisa Rumi, Daniela Pietra, Virginia Ferretti, Thorsten Klampfl, Ashot S Harutyunyan, Jelena D Milosevic, Nicole C C Them, Tiina Berg, Chiara Elena, Ilaria C Casetti,[...]. Blood 2014
407
13

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Animesh D Pardanani, Ross L Levine, Terra Lasho, Yana Pikman, Ruben A Mesa, Martha Wadleigh, David P Steensma, Michelle A Elliott, Alexandra P Wolanskyj, William J Hogan,[...]. Blood 2006
767
13

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Robyn M Emanuel, Amylou C Dueck, Holly L Geyer, Jean-Jacques Kiladjian, Stefanie Slot, Sonja Zweegman, Peter A W te Boekhorst, Suzan Commandeur, Harry C Schouten, Federico Sackmann,[...]. J Clin Oncol 2012
269
12

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Tiziano Barbui, Ayalew Tefferi, Alessandro M Vannucchi, Francesco Passamonti, Richard T Silver, Ronald Hoffman, Srdan Verstovsek, Ruben Mesa, Jean-Jacques Kiladjian, Rȕdiger Hehlmann,[...]. Leukemia 2018
282
12

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
Naseema Gangat, Domenica Caramazza, Rakhee Vaidya, Geeta George, Kebede Begna, Susan Schwager, Daniel Van Dyke, Curtis Hanson, Wenting Wu, Animesh Pardanani,[...]. J Clin Oncol 2011
632
11

Efficacy and safety of low-dose aspirin in polycythemia vera.
Raffaele Landolfi, Roberto Marchioli, Jack Kutti, Heinz Gisslinger, Gianni Tognoni, Carlo Patrono, Tiziano Barbui. N Engl J Med 2004
642
11

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Dana E Rollison, Nadia Howlader, Martyn T Smith, Sara S Strom, William D Merritt, Lynn A Ries, Brenda K Edwards, Alan F List. Blood 2008
438
10

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
A Kaifie, M Kirschner, D Wolf, C Maintz, M Hänel, N Gattermann, E Gökkurt, U Platzbecker, W Hollburg, J R Göthert,[...]. J Hematol Oncol 2016
102
10


Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
Alessandra Carobbio, Juergen Thiele, Francesco Passamonti, Elisa Rumi, Marco Ruggeri, Francesco Rodeghiero, Maria Luigia Randi, Irene Bertozzi, Alessandro M Vannucchi, Elisabetta Antonioli,[...]. Blood 2011
281
10

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.
T Barbui, A M Vannucchi, V Buxhofer-Ausch, V De Stefano, S Betti, A Rambaldi, E Rumi, M Ruggeri, F Rodeghiero, M L Randi,[...]. Blood Cancer J 2015
129
10

Targeted deep sequencing in polycythemia vera and essential thrombocythemia.
Ayalew Tefferi, Terra L Lasho, Paola Guglielmelli, Christy M Finke, Giada Rotunno, Yoseph Elala, Annalisa Pacilli, Curtis A Hanson, Alessandro Pancrazzi, Rhett P Ketterling,[...]. Blood Adv 2016
184
10




Epidemiology of MPN: what do we know?
L A Anderson, M F McMullin. Curr Hematol Malig Rep 2014
23
39

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.
Alexandra P Wolanskyj, Susan M Schwager, Rebecca F McClure, Dirk R Larson, Ayalew Tefferi. Mayo Clin Proc 2006
231
9

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Alessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N Harrison, Fabrizio Pane, Pierre Zachee, Ruben Mesa,[...]. N Engl J Med 2015
511
9

Cardiovascular events and intensity of treatment in polycythemia vera.
Roberto Marchioli, Guido Finazzi, Giorgina Specchia, Rossella Cacciola, Riccardo Cavazzina, Daniela Cilloni, Valerio De Stefano, Elena Elli, Alessandra Iurlo, Roberto Latagliata,[...]. N Engl J Med 2013
464
9

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Francesco Passamonti, Chiara Elena, Susanne Schnittger, Radek C Skoda, Anthony R Green, François Girodon, Jean-Jacques Kiladjian, Mary Frances McMullin, Marco Ruggeri, Carles Besses,[...]. Blood 2011
150
9


Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013.
Ja Min Byun, Young Jin Kim, Taemi Youk, John Jeongseok Yang, Jongha Yoo, Tae Sung Park. Ann Hematol 2017
17
52

Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms.
Lesley A Anderson, Andrew S Duncombe, Maria Hughes, Moyra E Mills, Jessica C Wilson, Mary F McMullin. Am J Hematol 2012
34
23


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.